2:34:17 PM PDT - Tuesday, July 14th, 2020

Novavax Analyst Says COVID-19 Vaccine Could Net $400M In Yearly Sales  

By Editor - Mon Jun 29, 5:56 pm

  • Comments Off on Novavax Analyst Says COVID-19 Vaccine Could Net $400M In Yearly Sales

Novavax, Inc. (NASDAQ: NVAX) shares are on a dream run this year amid catalysts including its COVID-19 vaccine program.The Novavax Analyst: Vernon Bernardino reiterated a top pick Buy rating on Novavax and raised the price target from $50 to $101. The Novavax Thesis: Novavax's COVID-19 vaccine candidate NVX-CoV2373 is likely a sustainable long-term market opportunity, Bernardino said in a Monday note. (See his track record here.)H.C. Wainwright held a virtual fireside chat with Novavax executives Thursday. The $388 million in CEPI funding for Novavax de-risks clinical development of the vaccine candidate, the analyst said. Novavax is capable of being a robust competitor against larger vaccine makers, likely helping it realize over $400 million in annual sales of NVX-CoV2373, he said.

The rest is here:

Novavax Analyst Says COVID-19 Vaccine Could Net $400M In Yearly Sales

  • Comments Off on Novavax Analyst Says COVID-19 Vaccine Could Net $400M In Yearly Sales

Leave a Reply

Comments are closed on this post.